TY - JOUR
T1 - Exploring the therapeutic potential of Caralluma fimbriata for antioxidant and diabetes management
T2 - a 28-day rat model study
AU - Arif, Aleena
AU - Sultan, M. Tauseef
AU - Nazir, Fahid
AU - Ahmad, Khalil
AU - Kashif, Muhammad
AU - Ahmad, Muhammad Mahboob
AU - Shehzad, Farooq Khurum
AU - Nazir, Muhammad Altaf
AU - Mushtaq, Shehla
AU - Khalid, Muhammad Usman
AU - Noman, Ahmad Mujtaba
AU - Raza, Hassan
AU - Israr, Muhammad
AU - Sohail, Hira
AU - Rocha, João Miguel
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press. All rights reserved.
PY - 2024/8/1
Y1 - 2024/8/1
N2 - This study evaluated the anti-oxidant and anti-diabetic potential of Caralluma fimbriata (CF) in 28-days rat modelling trial. Diabetes is a chronic disorder characterized by elevated blood glucose levels and insulin resistance and cause microvascular and macrovascular issues. Caralluma fimbriata was evaluated for its nutritional composition along with anti-oxidant potential of CF powder (CFP) and CF extract (CFE) using total phenolic contents (TPC), 2,2-diphenyl-1-picrylhydrazyl (DPPH) and ferric ion reducing antioxidant power (FRAP) assays. Furthermore, anti-diabetic potential was computed by dividing rats into four groups of 5 individuals each. Rats of Group I was non-diabetic and no supplementation was given while rats of group II were diabetic and no supplementation was given. While group III and group IV rats were diabetic and received CFP and CFE supplementation respectively. CF powder’s TPC, and DPPH and FRAP activity were observed maximum at 44.17 ± 0.006 (μgFe/g) in water, 68.75 ± 0.49 (μgFe/g) in acetone and 800.81 ± 0.99 (μgFe/g) in hexane. Supplementation of CFP and CFE reduced blood glucose effectively i.e. (125.00 ± 4.04 and 121.00 ± 4.49 mg/dL, respectively). Moreover, the consumption of C. fimbriata can be helpful in the management of diabetes mellitus due to its glucose lowering potential, anorexic effects, anti-oxidant potential and α-amylase inhibition.
AB - This study evaluated the anti-oxidant and anti-diabetic potential of Caralluma fimbriata (CF) in 28-days rat modelling trial. Diabetes is a chronic disorder characterized by elevated blood glucose levels and insulin resistance and cause microvascular and macrovascular issues. Caralluma fimbriata was evaluated for its nutritional composition along with anti-oxidant potential of CF powder (CFP) and CF extract (CFE) using total phenolic contents (TPC), 2,2-diphenyl-1-picrylhydrazyl (DPPH) and ferric ion reducing antioxidant power (FRAP) assays. Furthermore, anti-diabetic potential was computed by dividing rats into four groups of 5 individuals each. Rats of Group I was non-diabetic and no supplementation was given while rats of group II were diabetic and no supplementation was given. While group III and group IV rats were diabetic and received CFP and CFE supplementation respectively. CF powder’s TPC, and DPPH and FRAP activity were observed maximum at 44.17 ± 0.006 (μgFe/g) in water, 68.75 ± 0.49 (μgFe/g) in acetone and 800.81 ± 0.99 (μgFe/g) in hexane. Supplementation of CFP and CFE reduced blood glucose effectively i.e. (125.00 ± 4.04 and 121.00 ± 4.49 mg/dL, respectively). Moreover, the consumption of C. fimbriata can be helpful in the management of diabetes mellitus due to its glucose lowering potential, anorexic effects, anti-oxidant potential and α-amylase inhibition.
KW - Anti-oxidant potential
KW - Blood glucose
KW - Caralluma fimbriata
KW - Diabetes
UR - http://www.scopus.com/inward/record.url?scp=85197291838&partnerID=8YFLogxK
U2 - 10.1093/toxres/tfae094
DO - 10.1093/toxres/tfae094
M3 - Article
C2 - 38957782
AN - SCOPUS:85197291838
SN - 2045-452X
VL - 13
JO - Toxicology Research
JF - Toxicology Research
IS - 4
M1 - tfae094
ER -
